New York, New York--(Newsfile Corp. - September 2, 2025) - OS Therapies Inc. (OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology ...
Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results